Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta. Aug. 29, 2022 6:30 AM ET Kineta, Inc. (KANT) ...

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV ...

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ...

BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ...

Seattle biotech company Kineta is going public through a merger with Yumanity Therapeutics, a neurosciences company based in Boston.Yumanity will also sell part of its pipeline to Johnson ...

Yumanity Therapeutics is cutting 60% of its workforce by April, while not-so-subtly asking for buyers as the neurodegenerative-focused biotech's early promise begins to fade.

The raise comes after Kineta went public in December through a reverse merger with Boston-based biotech Yumanity Therapeutics Inc. Seattle-based biotech Kineta Inc. has raised about $6 million ...

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for YMTX is 37.9.

Clinical efforts expanding to three programs consisting of: the on-going Phase 1b portion of the YTX-7739 Phase 1 program in Parkinson’s disease patients with top line results expected in mid ...

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV ...